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Abstract
Background: Cigarette smoking is a major risk factor for head and neck cancer (HNC). To
our knowledge, low cigarette smoking (<10 cigarettes per day) has not been extensively
investigated in fine categories or among never alcohol drinkers.
Methods: We conducted a pooled analysis of individual participant data from 23
independent case-control studies including 19 660 HNC cases and 25566 controls. After
exclusion of subjects using other tobacco products including cigars, pipes, snuffed
or chewed tobacco and straw cigarettes (tobacco product used in Brazil), as well as
subjects smoking more than 10 cigarettes per day, 4093 HNC cases and 13 416
controls were included in the analysis. The lifetime average frequency of cigarette
consumption was categorized as follows: never cigarette users, >0–3, >3–5, >5–10
cigarettes per day.
Results: Smoking >0–3 cigarettes per day was associated with a 50% increased risk of
HNC in the study population [odds ratio (OR)¼1.52, 95% confidence interval (CI): (1.21,
1.90). Smoking >3–5 cigarettes per day was associated in each subgroup from OR¼ 2.01
(95% CI: 1.22, 3.31) among never alcohol drinkers to OR¼ 2.74 (95% CI: 2.01, 3.74) among
women and in each cancer site, particularly laryngeal cancer (OR¼ 3.48, 95% CI: 2.40,
5.05). However, the observed increased risk of HNC for low smoking frequency was not
found among smokers with smoking duration shorter than 20 years.
836 International Journal of Epidemiology, 2016, Vol. 45, No. 3
Conclusion: Our results suggest a public health message that low frequency of cigarette
consumption contributes to the development of HNC. However, smoking duration seems
to play at least an equal or a stronger role in the development of HNC.
Key words: Head and neck cancer, low frequency cigarette smoking, risk factors, pooled analysis
Introduction
Cigarette smoking is a well-established risk factor for head
and neck cancer (HNC) with a well-defined dose-response
relationship for duration and frequency of use.1,2 Yet, in
several epidemiological studies the lowest category of to-
bacco smoking has been defined as smoking 10 cigarettes
per day. To our knowledge, only three studies have investi-
gated the risk of HNC among participants smoking less
than 10 cigarettes per day: Polesel et al.,3 using cubic re-
gression spline model among male current smokers only
(1241 upper aerodigestive tract (UADT) cancer cases and 2
835 controls), showed evidence for an increased risk of
oral cavity and pharyngeal cancer beginning at two cigar-
ettes per day, and an increased risk of laryngeal cancer be-
ginning at five cigarettes per day. Tuyns et al.4 showed
evidence for an increased risk of endolarynx (OR¼ 2.37,
95% CI: 1.3, 4.3) and of hypopharynx (OR¼ 4.18, 95%
CI: 1.9, 9.3) associated with smoking 1 to 7 cigarettes per
day compared with never smokers, adjusted for alcohol
consumption. McLaughlin et al.5 reported similar results
in a 1–9 cigarettes per day category: OR¼5.2 (95% CI:
1.8, 15) for pharyngeal cancer. However, no analyses were
conducted among finer cigarette smoking frequency cate-
gories or specific subgroups such as never alcohol drinkers.
Few studies have been able to address the risk of HNC
among smokers of few cigarettes per day, due to the inad-
equate number of cases smoking less than 10 cigarettes per
day. Consequently, either spline regression models needed
to be utilized or broader categories of smoking frequency
used.
The International Head and Neck Cancer Epidemiology
(INHANCE) consortium was established in 2004 to ex-
plore the potential head and neck risk factors that were
difficult to evaluate in individual studies due to limited
sample size. To participate in the INHANCE consortium,
studies should provide individual participant data, with
data available on demographic and tumour characteristics,
alcohol consumption and tobacco use habits.6,7. Individual
participant data allow re-analysis with new hypotheses for-
mulated, various adjustments and specific subgroup
analyses.
The purpose of this study is to assess the dose-response
relationship between cigarette smoking and the risk of
HNC among subjects smoking less than 10 cigarettes per
day with better precision, while taking into account poten-
tial confounding and effect modifications. This analysis on
low frequency of cigarette consumption was proposed to
be performed within the INHANCE consortium database.
Methods
The version 1.4 of the INHANCE pooled dataset is an up-
date of the version 1.0, previously described by Hashibe
et al.7 At the time of this analysis, the INHANCE V1.4
dataset included 29 case-control studies with 21 373 HNC
cases and 29 548 controls.
For this analysis, we pooled data from 23 studies
(Table 1) with available information on cigarette, cigar
and pipe smoking status, duration and frequency, satisfy-
ing the criteria for the random-effect model used (each cat-
egory of the low frequency of cigarette smoking variable
should have at least one case or one control) including
19 660 cases and 25 566 controls. We then excluded sub-
jects missing information for age, sex or race and cases
missing the subsite of HNC (110 cases and 127 controls).
Then, to focus on the association with low cigarette
Key Messages
• There is no harmless level of cigarette consumption. Even smoking >0–3 cigarettes per day is associated with an
increased HNC risk.
• This association between low frequency of cigarette consumption and HNC risk is consistent across subsites of head
and neck cancer and among never alcohol drinkers.
• Smoking duration plays at least an equal or a stronger role compared with low frequency of cigarettes smoking in
the development of HNC.
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smoking frequency and to avoid residual effects from other
tobacco product, users of cigar, pipe, chew or snuff tobacco
or straw cigarettes were excluded (3206 cases and 2913 con-
trols). As the aim of the paper is to focus on low frequency
of cigarette smoking, subjects smoking more than 10 cigar-
ettes per day were excluded (12 251 cases and 9110 con-
trols). The final analysis dataset included 4093 HNC cases
and 13 416 controls from the 23 studies. Of the 3260 HNC
cases from studies with histological information, 3067
(94.1%) were squamous cell carcinoma (SCC).
The number of cigarettes per day was defined differ-
ently among studies. It was either a lifetime average con-
sumption (the Houston, Tampa, Puerto Rico, Rome,
North Carolina (1994–97), Milan (1984–989), Aviano,
Italy multicentre, Switzerland, New York multicentre,
Iowa, US multicentre, Seattle-Leo, Western Europe, North
Carolina (2002–06) studies) or a period-specific frequency,
usually by decades, changing habits or changing brand
period (the Los Angeles, Seattle, Boston, Central
Europe, International multicentre, Latin America, Sao
Paulo, Germany-Heidelberg studies). In the pooled ana-
lysis we used the lifetime average daily consumption by
adding the information when it was directly available or
calculating it by weighing each frequency of cigarette
smoking by its specific duration of consumption. We also
added a reference that provides more details (Hashibe
et al. 2009).8
The frequency of cigarette smoking was defined in four
categories (never cigarette users, >0–3 cigarettes per day,
>3–5, >5–10) and analyses were conducted in the overall
study population, among never alcohol users, for subsites
of HNC (oral cavity, hypopharynx, oropharynx, oral cav-
ity/pharynx not specified, and larynx, detailed in Hashibe
et al. 2007),7 by gender and among the different categories
of duration of cigarette smoking and age at start of
smoking cigarettes. One additional variable was created:
combining low frequency of cigarette smoking categories
and duration of cigarette smoking categories (<¼10 years,
10–20 years and >20 years).
Statistical analysis
The association of low-frequency cigarette smoking with
HNC was assessed by estimating odds ratios and 95% con-
fidence intervals based on unconditional logistic regression
models. To calculate summary estimates of associations,
the study-specific estimates were included in a multivariate
two-stage random-effects logistic regression model that
included the DerSimonian and Laird estimator9 which
allows for unexplained sources of heterogeneity among
studies. Pooled odds ratios were also estimated with a
fixed-effects logistic regression model that adjusted for age
(5-year categories), sex, education (categorical), race/ethni-
city, study/study centre and number of alcoholic drinks per
day (categorical). Number of drinks per day was set as a
categorical variable to minimize the impact of the highest
values. The Latin America and Sao Paulo studies did not
assess race/ethnicity, thus we classified the subjects as a
separate category ‘Latin Americans-Brazilian’.
Since 246 cases and 454 controls were missing educa-
tion level, we applied multiple imputations (five imput-
ations) with the PROC MI procedure in SAS. We assumed
that the education data were missing at random (i.e.
whether education was missing or not did not depend on
any other unobserved or missing values.10 We used the lo-
gistic regression model11 to predict education level with
age, sex, race/ethnicity, study centre and case/control sta-
tus within each region (Europe, North America, Latin
America and Asia) separately. The logistic regression re-
sults to assess summary estimates for low cigarette smok-
ing frequency for the five imputations were combined by
the PROC MIANALYZE procedure.
We tested for heterogeneity across studies, using a likeli-
hood ratio test derived from fitting a model with and a
model without a product term between low cigarette
smoking and the study indicator. Then, we compared twice
the difference of the log likelihood ratio of these two mod-
els, with a chi square distribution. The degree of freedom
of the test was the number of studies minus one. When het-
erogeneity between studies was detected (P< 0.05), the
random-effect estimates were reported, otherwise the
fixed-effects estimates were reported. We examined
whether the results from the two-stage random-effects
model and the fixed-effects logistic regression model were
comparable in magnitude of effect. When random-effect
estimates were estimated, individual studies missing cases
or controls for any of the low cigarette consumption fre-
quency categories were excluded, in order to have homoge-
neous contribution of studies across categories. We also
conducted influence analysis, where each study was
excluded one at a time to assure that the statistical signifi-
cance and magnitude of the overall summary estimate was
not dependent on any particular study. The trend test used
for the analysis was a Cochrane–Armitage test.
A specific analysis was conducted after exclusion of
oropharyngeal cancer cases. There is strong evidence that a
large proportion of oropharyngeal cancers are caused by
human papillomaviruses and are not related to tobacco
smoking.12,13 Analyses were then stratified by cancer site,
age category (<40, 40–<45, 45–<50, 50–<55, 55–<60,
60–<65, 65–<70, 70–<75, >¼ 75 years old), sex, race/
ethnicity, education level, source of control subjects (hos-
pital-based vs population-based), and geographical region
(Europe, North America, South/ Central America, others).
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We also repeated the analyses restricting the cases to SCC
histology within the set of studies that had collected hist-
ology information.
Results
The distributions of cases and controls by selected charac-
teristics are reported in Table 2. The proportion of cigar-
ette smokers smoking a lifetime average 5 cigarettes per
day was 72.8% among controls and 27.2% among cases.
The highest proportion of smokers of 5 cigarettes per day
were from the Boston study (63.5%) and the Los Angeles
study (57.4%). Women were more likely than men to
smoke a lifetime average of 5 cigarettes per day (43.0%
vs 33.8%). Participants smoking 5 cigarettes per day
were more likely to start smoking at a later age, for a
shorter duration and to be former smokers (participants
who stopped smoking for more than 1 year before answer-
ing the questionnaire) compared with participants smoking
more than 5 cigarettes per day (P< 0.01 for each
comparison).
HNC risk increased with greater smoking frequency in
the overall study population, after exclusion of oropharyn-
geal cancer cases and among never alcohol drinkers (P for
trend <0.01; Table 3). The OR for the category of >0–3
cigarettes/day was 1.52 (95% CI: 1.21, 1.90) for the over-
all study population and 1.35 (95% CI: 0.83, 2.18) among
never alcohol drinkers. The association between smoking
>3–5 cigarettes per day and the risk of HNC was observed
among the overall study population (OR¼ 2.14, 95% CI:
1.73, 2.65) and among never alcohol drinkers (OR¼ 2.01,
95% CI: 1.22, 3.31).
Results by HNC subsite demonstrated the strongest
dose-response relationship for hypopharyngeal and laryn-
geal cancer (P for trend <0.01; Table 4). For these subsites,
the OR for smokers of >0–3 category cigarettes/day was
2.43 (95% CI: 1.23, 4.79) for hypopharynx and 2.68
(95% CI: 1.82, 3.95) for larynx.
Although the point estimates were slightly higher among
women than men, the 95% CIs overlapped (Table 5). We
observed that women smoking >0–3 cigarettes per day had
an increased risk of HNC (OR¼ 1.77, 95% CI: 1.30, 2.40)
compared with never smokers. For the combination of fre-
quency and duration of smoking, we observed an associ-
ation between HNC and each stratum of the low frequency
of cigarette consumption with the highest stratum of smok-
ing duration (Table 6). Figure 1 shows a forest plot of the
study-specific estimates for the risk of HNC associated
with smoking 3 to 5 cigarettes per day. All studies but
Switzerland, Tampa and Los Angeles showed an increased
risk of HNC for smoking 3 to 5 cigarettes per day. There
was also an increased risk of smoking >0 to 3 cigarettes
per day among current smokers (OR¼ 2.07, 95% CI: 1.53,
2.81) and among former smokers (OR¼ 1.32, 95% CI:
1.05, 1.66).
An analysis stratified by study design showed positive
monotonic trends of increasing risks with increasing
Table 2. Selected characteristics of the head and neck case
subjects and controls subjectsc from the INHANCE consortium
Cases Controls
n % n %
Total 4093 13416
Age categories (years)
<40 331 8.1 1149 8.6
40–<45 235 5.7 939 7.0
45–<50 369 9.0 1353 10.1
50–<55 521 12.7 1876 14.0
55–<60 628 15.3 2065 15.4
60–<65 597 14.6 1927 14.4
65–<70 519 12.7 1806 13.5
70–<75 476 11.6 1378 10.3
>¼75 417 10.2 923 6.9
Pa <0.0001
Sex
Women 1678 41.0 5875 43.8
Men 2415 59.0 7541 56.2
Pa 0.002
Race
White 2655 64.9 9968 74.3
Black 273 6.7 655 4.9
Hispanic 103 2.5 330 2.5
Asian 111 2.7 472 3.5
Other 30 0.7 110 0.8
Braziliand 921 22.5 1881 14.0
Pa <0.0001
Education
None 129 3.4 272 2.1
Junior high school 1447 37.6 4533 35.0
Some high school 560 14.6 1856 14.3
High school graduate 513 13.3 1674 12.9
Vocational, some college 602 15.7 2343 18.1
Some graduation 596 15.5 2284 17.6
Missingb 246 454
Pa <0.0001
Subsite
Oral cavity 1327 32.4
Oropharynx 1179 28.8
Hypopharynx 230 5.6
Oral cavity/pharynx NOSe 488 11.9
Larynx 797 19.5
Head and neck overlap 72 1.8
aChi-square two-sided test.
bRome does not have information on education.
cMissing for age, sex, race and subsite as well as users of pipe or cigar or
chewed tobacco. Snuffed tobacco or straw cigarettes were excluded.
dOnly cases and controls from Sao Paulo and Latin America study.
eNot Otherwise Specified.
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frequency of cigarette smoking for both hospital-based
(n¼ 15) and population-based (n¼9) studies (the Western
Europe study includes studies with both population-based
and hospital-based controls), with a slightly weaker trend
in population-based studies (OR¼ 1.64, 95% CI: 0.90,
3.00; OR¼ 1.93, 95% CI: 1.31, 2.85; OR¼ 2.51, 95% CI:
1.50, 4.18 for> 0–3, >3–5 and >5–10 cigarettes/day, re-
spectively; P for trend <0.01). When the analysis by region
was conducted, an apparent positive trend of increasing
risks with increasing frequency of cigarette smoking was
observed in each region. Such relationship was found to be
strongest in Europe and Latin America. The risk of
HNC for smoking >0 to 3 cigarette per day was
OR¼ 1.82 (95% CI: 1.15, 2.86) in Europe and OR¼1.98
(95% CI: 1.15, 3.39) in Latin America. Analyses re-
stricted to squamous cell carcinoma yielded similar results
(see Appendix Table 1A, available as Supplementary data
at IJE online).
We additionally adjusted, when the information was
available, for body mass index (BMI) (all studies except for
Rome, Seattle, International multicentre, Iowa, Central
Europe, Sao Paulo, Germany-Heidelberg) and for family
history of HNC (all studies except for Rome, Seattle, New
York multicentre, Iowa, Western Europe and Seattle-Leo).
Table 3. Lifetime average daily number of cigarettes smoked and the risk of HNC, among the overall population and among
never alcohol drinkers, in the INHANCE consortium
Number of
cigarettes
smoked per day
Overalla Never alcohol drinkersb Overall without oropharyngeal casesc
Cases Controls ORd 95% CI Cases Controls ORd 95% CI Cases Controls ORd 95% CI
Never 1939 9239 1.00 Ref 724 2836 1.00 Ref 1635 8821 1.00 Ref
>0–3 250 793 1.52 (1.21, 1.90) 41 123 1.35 (0.83, 2.18) 212 779 1.56 (1.25, 1.93)
>3–5 314 710 2.14 (1.73, 2.65) 38 89 2.01 (1.22, 3.31) 278 680 2.30 (1.88, 2.81)
>5–10 1258 2215 2.60 (2.00, 3.40) 131 286 2.12 (1.48, 3.02) 1137 2125 2.98 (2.31, 3.82)
Missing 332 459 11 13 299 451
P-value <0.01 <0.01 <0.01
P for heterogeneity
across studies
<0.01 <0.01 <0.01
aAdjusted on age (categorical), sex, race, education level, centres and drinks per day (categorical). The 23 studies were included.
bAdjusted on age (categorical), sex, race, education level and centres. The Switzerland, New York multicentre, Iowa, Los Angeles, Houston, Puerto Rico, Latin
America, IARC multicentre, Sao Paulo, Western Europe and North Carolina population-based studies were included.
cAdjusted on age (categorical), sex, race, education level, centres and drinks per day. The 23 studies, except for the North Carolina and Tampa studies, were
included.
dRandom-effect model used.
Table 4. Lifetime average daily number of cigarettes smoked and the risk of HNC by subsite of cancer, in the INHANCE consortium
Daily number
of cigarette
smoked
Oral cavitya Hypopharynxb Oropharynxc Larynxd
Cases Controls ORe 95% CI Cases Controls ORe 95% CI Cases Controls ORe 95% CI Cases Controls ORe 95% CI
Never 653 6309 1.00 38 3521 1.00 520 7368 1.00 203 6010 1.00
>0–3 62 548 1.48 (1.04, 2.09) 13 3443 2.43 (1.23, 4.79) 70 661 1.57 (1.10, 2.23) 58 581 2.68 (1.82, 3.95)
>3–5 79 474 2.23 (1.45, 3.42) 17 310 3.35 (1.78, 6.29) 64 528 2.17 (1.53, 3.06) 74 518 3.48 (2.40, 5.05)
>5–10 291 1501 2.18 (1.68, 2.83) 71 1032 4.38 (2.82, 6.82) 323 1724 2.85 (1.89, 4.08) 309 1543 5.21 (4.07, 6.68)
Missing 104 407 8 244 51 398 92 324
P-value <0.01 <0.01 <0.01 <0.01
P for
heterogeneity
across studies
<0.01 <0.01 <0.01 <0.01
Adjusted on age (categorical), race, education level, centres and drinks per day (categorical).
aThe Aviano, Boston, Los Angeles, Milan, North Carolina, Rome, Switzerland, Tampa, Seattle-LEO and Germany-Heidelberg studies were not included.
bOnly Aviano, Italy multicentre, New York, Latin America, US multicentre, Seattle-LEO and Western Europe studies were included.
cThe Milan, Central Europe, Seattle, North Carolina, Tampa, Boston, and Germany-Heidelberg studies were not included.
dOnly Milan, Central Europe, Italy Multicentre, New York, Iowa, Los Angeles, Latin America, Boston, Rome, Sao Paulo, Seattle-LEO, Western Europe,
Germany-Heidelberg and North Carolina population-based studies were included.
eRandom-effect models.
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The magnitudes of the associations were similar
to those observed without the additional adjustments
(see Appendix Table 1A, available as Supplementary data
at IJE online). Analysis of passive smoking was not con-
ducted as this information was only available in six studies
(Central Europe, Latin America, Puerto Rico, Tampa, Los
Angeles and Houston), and this would have resulted in a
restricted number of cases and controls. However, based
on our previous analysis on passive smoking,14 the modest
association with passive smoking was observed among
never tobacco users. Thus, we suspect the dose-response
relationship among smokers presented here would not be
significantly biased.
Finally, we conducted sensitivity analyses to assess
whether or not one or several studies had a strong influ-
ence on the observed associations. When we omitted each
study from the analysis one at a time, the Aviano and the
Tampa studies accounted for heterogeneity the most.
When the Aviano study was not included, the summary es-
timate for smoking 3 to 5 cigarettes per day compared
with never smokers was 2.04 (95% CI: 1.69, 2.46) and
when the Tampa study was not included, the summary es-
timate was 2.18 (95% CI: 1.76, 2.69) as compared with
the overall summary estimate of 2.14 (95% CI: 1.73,
2.65). When both studies were excluded from the summary
estimate, the OR was 2.06 (95% CI: 1.71, 2.49).
The sensitivity analysis was also conducted for smoking
>0 to 3 cigarettes per day. When we omitted each study
from the analysis one at a time, the Seattle and the North
Carolina (hospital-based) studies accounted for heterogen-
eity the most. When the Seattle study was not included, the
summary estimate for smoking >0 to 3 cigarettes per day
compared with never smokers was 1.55 (95% CI: 1.24,
1.95) and when the North Carolina study was not
included, the summary estimate was 1.50 (95% CI: 1.19,
1.88) as compared with the overall summary estimate of
1.52 (95% CI: 1.21, 1.90). When both studies were
excluded from the summary estimate, the OR was 1.54
(95% CI: 1.22, 1.93).
Discussion
The ability to pool individual data from studies allowed us
to detect an increased risk of HNC with smoking less than
10 cigarettes more precisely than it has been reported
Table 5. Lifetime average daily number of cigarettes smoked and the risk of HNC by gender, in the INHANCE consortium
Daily number of
cigarettes smoked
Mena Womenb
Cases Controls ORc 95% CI Cases Controls ORc 95% CI
Never 853 4099 1.00 882 3763 1.00
>0–3 141 480 1.39 (0.96, 2.01) 101 278 1.77 (1.30, 2.40)
>3–5 160 409 2.05 (1.39, 3.02) 118 200 2.74 (2.01, 3.74)
>5–10 854 1420 2.83 (2.01, 3.98) 330 556 2.67 (2.02, 3.53)
Missing 235 250 84 180
P-value <0.01 <0.01
P for heterogeneity
across studies
<0.01 <0.01
Adjusted on age (categorical), race, education level, centres and drinks per day (categorical).
aThe Boston, North Carolina, Tampa, Switzerland and Seattle-LEO studies were not included.
bThe Boston, Milan, Rome, Tampa and Germany-Heidelberg studies were not included.
cRandom-effect models.
Table 6. Adjusted OR (95% CI) of HNC by lifetime average
daily number of cigarettes smoked combined with duration
of cigarette smoking in years, in the INHANCE consortium
Cigarattes daily Cases Controls ORa,b 95% CI
Never smokers 1163 4329 1.00 Ref
>0–3 cig for <¼10 yrs 53 199 1.04 (0.75, 1.43)
>0–3 cig for >10–20 yrs 27 77 1.39 (0.88, 2.20)
>0–3 cig for >20–30 yrs 29 79 1.30 (0.83, 2.03)
>0–3 cig for >30 yrs 76 104 2.64 (1.92, 3.63)
>3–5 cig for <¼10 yrs 30 98 1.04 (0.68, 1.59)
>3–5 cig for >10–20 yrs 22 70 1.19 (0.72, 1.96)
>3–5 cig for >20–30 yrs 37 55 2.35 (1.52, 3.65)
>3–5 cig for >30 yrs 101 105 2.89 (2.13, 3.91)
>5–10 cig for <¼10 yrs 52 167 1.06 (0.76, 1.47)
>5–10 cig for >10–20 yrs 55 220 0.94 (0.68, 1.29)
>5–10 cig for >20–30 yrs 130 221 1.91 (1.49, 2.43)
>5–10 cig for >30 yrs 541 412 4.17 (3.54, 4.90)
Missing 229 164
P for heterogeneity 0.05
P for trend <0.01
Adjusted on age (categorical), race, education level, centres and drinks per
day (categorical); yrs, years.
aThe Los Angeles, International Multicentre, US multicentre, Sao Paulo,
Western Europe, North Carolina (population-based) studies were included.
bFixed-effect model.
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previously by Tuyns et al.4 and McLaughlin et al.5 and
highlighted an approximately 1.5-fold increased risk of
HNC for smoking >0 to 3 cigarettes per day and a more
than 2-fold increased risk of HNC for smoking >3 to 5 cig-
arettes per day. This also corroborates the results reported
by Polesel et al.3 that there is an increased risk regardless
of the number of cigarettes smoked per day. Polesel
showed evidence for an increased OR of UADT cancer for
smoking two cigarettes per day. The present analysis pro-
vides additional details for the finer categories of smoking
frequency with adequate sample size.
From a methodological point of view we decided to in-
vestigate the frequency of cigarette smoking as a categorical
variable with fine categories instead of a continuous vari-
able. Even though using a continuous variable might in-
crease the precision of the estimates, it implies making some
assumptions on the shape of the slope and might introduce
mis-specification bias. There is no need for such assump-
tions when using a categorical variable. The large number of
cases and controls provides for sufficient precision, and
keeps the results straightforward for interpretation.
The higher increased risk of laryngeal cancer with
cigarette smoking compared with the other head and neck
subsites is consistent with the previous findings12,13 and
with the previous reports from INHANCE studies that
active smoking is a stronger risk factor for laryngeal cancers
than for oral cavity cancer among never alcohol drinkers.7
The analysis combining the smoking frequency with
smoking duration is consistent with the previous observa-
tions that duration of smoking seems to play at least an
equal or a stronger role in the development of HNC4 even
among never alcohol drinkers.
A potential limitation with regards to the data pooling
was the variation of definition for ‘ever cigarette smokers’
(among whom the frequency of cigarette smoking was
measured) used in the different studies: ever smoked,
smoked 100 cigarettes in a lifetime, smoked 1 cigarette/
day for 1 year or 6 months, smoked 1 cigarette/week for
1 year or smoked half a pack/week for 1 year.
However, these different classifications are relatively
minor and likely to be non-differential between cases and
controls. Thus, this might lead to an underestimation of
the assessment. In addition, some individuals with very
minimal cigarette use may have been categorized as ‘never
cigarette users’ in the analysis due to the definition or the
wording of the questions. The studies with higher threshold
Figure 1. Forest plot of the risk of HNC associated with lifetime consumption of 3 to 5 cigarettes per day compared with never smokers, in the
INHANCE Consortium. Pop, population-based; hosp, hospital.
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for the classification were the Tampa study (smoking cigar-
ettes less than once a day for <1 year as never users of cigar-
ettes) and Latin America study (<1 cigarette per day for 1
year as never cigarette smokers). However, the ORs for the
lowest category of smokers (>0–3 per day) were not consist-
ently lower or higher for these studies compared with the
others included in our pooled analysis.
Recall bias may be another limitation for our pooled
analysis because information about cigarette smoking and
the other exposures was collected for cases after the
diagnosis of HNC. However, we observed associations
between low-frequency cigarette smoking in both hospital-
based and population-based studies, which may be
susceptible to recall bias in different degrees. In addition,
there might be residual confounding by the other risk fac-
tors. However, our study sample size allowed us to investi-
gate the association among never alcohol drinkers to
eliminate the possible residual confounding by alcohol
drinking. Additionally, further adjustment for body mass
index and family history of HNC did not support that the
observed association could be accounted for by these fac-
tors. Although heterogeneity across studies was important,
in the >0–3 and 3 to 5 cigarettes per day, the sensitivity
analyses showed that exclusion of studies contributing the
most in the heterogeneity did not lead to major changes in
the estimates for both categories.
Finally, as specified in the method section, analyses
were conducted on data from studies participating in the
INHANCE consortium. Some published and unpublished
studies might not be included, but publication bias is not a
concern for this type of analysis because we did not select
studies from the literature. Additionally, the large sample
size and the quality of the studies included allow our esti-
mates to be accurate.
In summary, this pooling project provides evidence for a
carcinogenic consequence of cigarette smoking at low fre-
quency. The results of this study send a public health mes-
sage to the community: there is no harmless level
of cigarette consumption, even smoking >0–3 cigarettes per
day is associated with an increased HNC risk. However,
smoking duration seems to play at least an equal or a stron-
ger role in the development of HNC in light smokers.
Supplementary Data
Supplementary data are available at IJE online.
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